- What makes clinical report translation different
- Regulatory requirements by authority and market
- The right translation process for regulatory submissions
- Factors that affect cost and turnaround
- M21Global: pharmaceutical translation for regulatory submissions
- Related Services
- Frequently Asked Questions
Submitting clinical reports to health authorities such as the EMA, FDA, or INFARMED requires translations that meet precise technical and regulatory standards. A terminology error or inconsistency between documents can delay approval or trigger a request for additional information. Understanding what is required before the process starts saves time and reduces risk.
What makes clinical report translation different
Clinical reports follow standardised formats. The Clinical Study Report (CSR) is structured according to ICH E3 guidelines, pharmacovigilance reports follow the PSUR/PBRER framework, and bioequivalence reports must comply with specific CTD module requirements. That standardisation does not simplify translation. It demands that linguists know each format in detail, understand where terminology diverges across language versions, and maintain exact alignment with validated terms in ICH, EMA, and WHO guidelines.
Terminology is the most critical factor. Terms such as *adverse event*, *primary endpoint*, *pharmacokinetics*, and *intent-to-treat population* have rigorously defined equivalents in each target language that cannot vary between sections of the same document. A translation that renders one concept with two different expressions introduces regulatory ambiguity, even if both terms are technically defensible in isolation.
Formatting and numerical data integrity are equally important. Tables, figures, and appendices are part of the report and must be translated or adapted with complete fidelity to the source values. Inconsistent handling of unit conversions, date formats, or confidence interval notation raises questions during regulatory review.
Regulatory requirements by authority and market
Each authority has its own language requirements. The EMA operates primarily in English, but national competent authorities within EU Member States may require translation into the local language at specific stages of the authorisation process. INFARMED accepts Portuguese and English for most national procedures but requires Portuguese for labelling and certain CTD modules in strictly national submissions.
Brazil's ANVISA requires documentation in Brazilian Portuguese, which means linguistic adaptation is necessary for documents originally drafted in European Portuguese. For FDA submissions, documents already in English do not require translation, but any foreign-language document forming part of a dossier must be accompanied by a certified translation.
Consistency across the dossier is a regulatory expectation, not just a quality preference. Translating clinical trial protocols for regulatory submission involves the same logic: the protocol, interim reports, and final CSR must use identical terminology throughout, so that reviewers can trace decisions and findings without ambiguity.
The right translation process for regulatory submissions
Regulatory documentation requires independent review and documented quality assurance. A single translator, however experienced, does not provide the level of traceability that health authorities expect to find in a complex submission dossier.
The appropriate process for this type of documentation includes:
- Translation by a specialist in medical-regulatory language, with direct experience of CSRs, PSURs, GCPs, and CTD modules
- Independent review by a second linguist with equivalent expertise
- Quality assurance review focused on terminological consistency, data integrity, and compliance with regulatory formats
- Glossary and translation memory management, to ensure consistency across all documents in the same dossier
- ISO 17100 certification, which documents the process and serves as evidence of quality for the authority
The same traceability requirements apply to technical files for medical devices. Medical device documentation translation for MDR compliance follows an equivalent logic: independent review and documented process are not optional for high-stakes regulatory submissions.
Using machine translation without substantive human review is a genuine regulatory risk. Health authorities do not accept AI-generated terminology errors as mitigating circumstances. Responsibility rests with the applicant.
Factors that affect cost and turnaround
The cost of translating clinical reports depends on several variables. Volume is the most obvious: a CSR can run between 100 and 500 pages, and a tight submission deadline may require parallel working across multiple specialist translators. The language pair also matters: the availability of medical-regulatory specialists varies significantly between common and less common combinations.
Therapeutic complexity is a further factor. An oncology or advanced therapy report requires a different level of specialist knowledge than a Phase I study in a well-established area. The existence of prior glossaries and translation memories from the same clinical programme reduces effort and improves consistency across the dossier.
For an accurate estimate, it is necessary to share the document or a representative sample, specify the target authority, and confirm the available turnaround time. There is no meaningful price without that information.
M21Global: pharmaceutical translation for regulatory submissions
M21Global works with pharmaceutical manufacturers, CROs, and regulatory consultancies on the translation of clinical reports for submission to authorities including the EMA, FDA, INFARMED, and ANVISA. The process follows the Estratégica workflow: three linguists, independent review, and ISO 17100:2015 certification audited by Bureau Veritas. Glossaries are managed at programme level, ensuring consistency between the protocol, interim reports, and final CSR. Further detail is available on the M21Global pharmaceutical translation services page. For submissions with a defined deadline, contact M21Global with the document volume, language pair, and target authority to receive a detailed quote.
Related Services
Request a free medical translation quote
- Request a free medical translation quote
- Medical Device Documentation Translation Mdr Compliance
- Translating Clinical Trial Protocols Regulatory Submission
- Drug Labeling Translation
Frequently Asked Questions
Does a clinical report translation need ISO 17100 certification?
Health authorities do not formally mandate ISO 17100, but they expect documented and traceable translation processes. ISO 17100 certification provides that evidence in a recognised form and reduces the risk of the translation process being questioned during regulatory review.
How long does it take to translate a Clinical Study Report?
A full CSR can range from 100 to 500 pages. Turnaround depends on volume, language pair, and whether existing glossaries and translation memories are available. For high-volume submissions with tight deadlines, parallel working across specialist teams is possible.
Does the FDA require certified translation of foreign-language documents?
Yes. Any foreign-language document included in an FDA submission dossier must be accompanied by a complete and accurate English translation, together with a statement from the translator certifying its accuracy.
What happens if there are terminology inconsistencies in a translated clinical report?
Inconsistencies can generate queries from the reviewing authority and, in more serious cases, delay or jeopardise approval. Managing glossaries at programme level across all documents in a dossier is the most effective way to prevent this.
Can machine translation be used for clinical report submissions?
Machine translation without substantive human review carries real regulatory risk. Health authorities hold the applicant responsible for errors in the dossier regardless of the tools used. Regulatory documentation requires a process with independent human review and documented quality assurance.
